Technical Analysis for EGRX - Eagle Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 44.2 1.47% 0.64
EGRX closed up 4.51 percent on Thursday, January 17, 2019, on 87 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical EGRX trend table...

Date Alert Name Type % Chg
Jan 17 Stochastic Reached Overbought Strength 1.47%
Jan 17 Weak + Overbought Other 1.47%
Jan 17 Overbought Stochastic Strength 1.47%
Jan 16 Shooting Star Candlestick Bearish 6.05%
Jan 16 Lizard Bearish Bearish Day Trade Setup 6.05%
Jan 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 6.05%
Jan 16 Overbought Stochastic Strength 6.05%
Jan 16 Upper Bollinger Band Touch Strength 6.05%
Jan 15 Stochastic Sell Signal Bearish 5.21%
Jan 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 5.21%

Older signals for EGRX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.
Is EGRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 85.66
52 Week Low 36.03
Average Volume 221,743
200-Day Moving Average 62.2196
50-Day Moving Average 45.1352
20-Day Moving Average 40.3435
10-Day Moving Average 41.793
Average True Range 2.1214
ADX 23.65
+DI 14.9583
-DI 16.7435
Chandelier Exit (Long, 3 ATRs ) 39.0358
Chandelier Exit (Short, 3 ATRs ) 42.3942
Upper Bollinger Band 43.9071
Lower Bollinger Band 36.7799
Percent B (%b) 0.95
BandWidth 17.666291
MACD Line -0.7319
MACD Signal Line -1.4281
MACD Histogram 0.6961
Fundamentals Value
Market Cap 660.76 Million
Num Shares 15.2 Million
EPS 5.96
Price-to-Earnings (P/E) Ratio 7.31
Price-to-Sales 3.34
Price-to-Book 4.96
PEG Ratio 0.95
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 47.75
Resistance 3 (R3) 47.38 45.62 47.05
Resistance 2 (R2) 45.62 44.55 45.80 46.82
Resistance 1 (R1) 44.59 43.89 45.10 44.96 46.59
Pivot Point 42.82 42.82 43.08 43.01 42.82
Support 1 (S1) 41.79 41.75 42.31 42.16 40.53
Support 2 (S2) 40.03 41.09 40.21 40.30
Support 3 (S3) 39.00 40.03 40.07
Support 4 (S4) 39.37